Skip to main
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is strategically positioned for growth through its innovative TRACER platform, which is anticipated to generate revenues from collaborations progressing toward clinical trials in the 2030s. The company has demonstrated promising preclinical results, such as VY1706's ability to significantly reduce tau messenger RNA and protein levels while ensuring lower liver exposure compared to traditional AAV9 approaches, suggesting enhanced efficacy and safety. Additionally, the recent advancements in non-viral delivery methods indicate a competitive edge in sustaining central nervous system exposure, reinforcing the potential for durable clinical benefits in treating severe neurological diseases.

Bears say

Voyager Therapeutics Inc. has faced significant challenges in advancing its gene therapy programs, leading to concerns about the viability of its pipeline and the potential for long-term profitability. The company's investment in AAV-based therapies has been met with setbacks, highlighting issues related to clinical trial outcomes and the competitive landscape in the gene therapy market. Additionally, financial data indicates rising operational costs and a need for substantial funding, which may dilute existing shareholder value and contribute to a negative perception regarding the stock.

Voyager Therapeutics (VYGR) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 4 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.